How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,320 results for

Instilling Eye Drops

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Evaluation of a New Method for Instilling Eye Drops

Evaluation of a New Method for Instilling Eye Drops Evaluation of a New Method for Instilling Eye Drops - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation of a New Method for Instilling Eye Drops (...) : The purpose of this project is to demonstrate that there is a new easier method to instill eye drops in ones own eye that is as effective as applying a drop directly to their open eye. The benefits of this new method include better medication compliance and reduced patient anxiety from instilling their eye drops. This secondary benefit should remove the "approach-avoidance response" that prompts some patients to delay or give-up on instilling their drops just to avoid the angst and frustration produced

2016 Clinical Trials

22. Ophthalmic Insert versus Eye Drops for Mydriasis in Neonates: A Randomized Clinical Trial. (Abstract)

Ophthalmic Insert versus Eye Drops for Mydriasis in Neonates: A Randomized Clinical Trial. Eye drop treatment routinely used to obtain mydriasis prior to fundoscopy in neonates requires repeated instillations of mydriatic agents that can lead to systemic side effects.The aim of this study was to compare the mydriatic efficacy and tolerance of administration of phenylephrine and tropicamide via the ophthalmic insert Mydriasert® versus standard eye drop treatment in neonates.In this prospective (...) , single-blinded, noninferiority study, 80 hospitalized neonates (age < 18 months) requiring bilateral fundus examination were randomized to receive eye drops (repeated instillations of 2.5% phenylephrine and 0.5% tropicamide) or the insert. The primary outcome was mydriasis suitable for fundoscopy 75 min after mydriatic agent introduction (T75).Mydriasis was successfully achieved in both eyes at T75 in 97.5% (n = 39/40) of the insert group patients versus 90% (n = 36/40) receiving eye drops (between

2018 Neonatology Controlled trial quality: uncertain

23. Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops

for non-invasive lipid layer thickness measurement, and the Oculus Keratograph (K5M) is used for non-invasive measurements of tear break-up time. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 35 participants Allocation: Randomized Intervention Model: Crossover Assignment Intervention Model Description: Single masked; randomized Masking: Single (Participant) Masking Description: Investigator instills known eye drop; masked (...) the increase in lipid layer thickness from baseline at 15 minutes and 1, 2, 4 and 6 hours after each eye drop has been instilled. Non-invasive measurements of tear break-up time will be also conducted at each visit. Subjects will then be dispensed the emollient eye drop (Systane® Complete) for use four times daily for one month and return to the study site for final measurements of dry eye symptoms, lipid layer thickness, and tear break-up time. The Stroboscopic Video Color Microscope of King-Smith is used

2018 Clinical Trials

24. Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children in the United Kingdom

by calculating the difference between the Accommodation Response (AR = near MSE (autorefractor)) and the Accommodation Stimulus. Spectacle correction [ Time Frame: Baseline - 24-months ] Current spectacle prescription. Eye drop tolerability [ Time Frame: Baseline - 24-months ] Assessed using a 4-point scale to quantify, from the point of view of the participant, (1) local irritation/stinging associated with eye drop instillation; (2) photophobia; and (3) difficulties reading and writing. Adverse event rates (...) Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children in the United Kingdom Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children in the United Kingdom - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2018 Clinical Trials

25. Tear osmolarity changes after use of hydroxypropyl-guar-based lubricating eye drops Full Text available with Trip Pro

-invasive tear break up time (NITBUT), conjunctival hyperemia, corneal and conjunctival staining were determined at baseline. Participants were instructed to instill one drop of a HP-guar-based drop QID in each eye for 3 weeks. At the follow-up visit, the symptoms and ocular surface parameters were reassessed. At this visit, one HP-guar drop was instilled into each eye and osmolarity was measured after 15 minutes, to examine short-term changes in osmolarity.Twenty-eight participants completed the study (...) Tear osmolarity changes after use of hydroxypropyl-guar-based lubricating eye drops To evaluate tear osmolarity after using a hydroxypropyl-guar (HP-guar)-based lubricating eye drop four times daily (QID) for 3 weeks.Thirty-one participants with dry eye disease (Ocular Surface Disease Index [OSDI] score ≥20 and tear osmolarity ≥300 mOsm/L in at least one eye) were enrolled in this prospective, dispensing, non-randomized study involving a baseline visit and 3-week follow-up. Tear osmolarity, non

2018 Clinical ophthalmology (Auckland, N.Z.)

26. Short-term effects of low-concentration atropine eye drops on pupil size and accommodation in young adult subjects Full Text available with Trip Pro

with concentrations of either 0.01%, 0.005%, or 0.001% in the evening. Baseline parameters were measured before atropine application. Changes of pupil sizes, under photopic and mesopic conditions, as well as accommodation amplitudes were observed over the next day and analyzed by paired the Wilcoxon signed-rank test.The pupil was significantly dilated 12 h after instillation of 0.01% atropine eye drops, both under photopic (3.3 ± 0.5 mm vs. 4.9 ± 0.9 mm) and mesopic (4.8 ± 0.7 mm vs. 6.1 ± 0.7 mm) conditions (...) Short-term effects of low-concentration atropine eye drops on pupil size and accommodation in young adult subjects A single eye drop containing 0.01% atropine every evening has previously been found to inhibit myopia progression in young adults. We have tested the short-term effects of very low-dose atropine eye drops on pupil sizes and accommodation in young adult subjects.Fourteen eyes of young adult subjects participated in the clinical observation. A single eye drop was applied

2018 Graefe's Archive for Clinical and Experimental Ophthalmology

27. Corneal Thickness Response after Anesthetic Eye Drops: Our Own Results and Meta-Analysis Full Text available with Trip Pro

Corneal Thickness Response after Anesthetic Eye Drops: Our Own Results and Meta-Analysis We aimed to test if there are different patterns in the central corneal thickness (CCT) response after instilling oxybuprocaine anesthetic eye drops and also to determine whether there is a significant change in the CCT. CCT was measured in 60 eyes of 60 healthy subjects before and during the hour after oxybuprocaine 0.4% eye drops were instilled. In addition, a systematic review and meta-analysis were (...) carried out in order to answer the following PICO (patient, intervention, comparison, and outcome) question: What effect do anesthetic eye drops have on CCT values? We found no significant changes in the mean CCT values during the hour's observation (ANOVA, p = 0.209), and the meta-analysis revealed no statistically significant changes in the CCT after anesthesia (Q-Value = 1.111; p value = 1.000; I2 = 0.000; Tau2 = 0.000; Stderr = 0.020). However, we found three CCT response patterns 5 minutes after

2018 BioMed research international

28. Effect of Atropine Eye Drops on Choroidal Thinning Induced by Hyperopic Retinal Defocus Full Text available with Trip Pro

thickness (SFCT, PFCT) were monitored with optical coherence tomography. On day 2, the procedure was repeated but the experimental eye had received one drop of 0.5% atropine 22 hours earlier.On day 1, eyes exposed to hyperopic defocus developed progressively thinner choroids (SFCT (baseline) = 253 ± 32 μm versus SFCT (40 mins) = 244 ± 31 μm, p = 0.004), whereas SFCT and PFCT in control eyes did not change (p > 0.17). On day 2 (22 hours after instilling atropine), baseline SFCT and PFCT were (...) Effect of Atropine Eye Drops on Choroidal Thinning Induced by Hyperopic Retinal Defocus To investigate the effects of atropine on choroidal thinning induced by hyperopic retinal defocus.Ten young adults with myopia (-1.00 D to -5.00 D) viewed a video at 6 metres for 60 minutes on successive days. On day 1, one eye (control) was distance corrected with a contact lens; the other (experimental) eye wore a contact lens imposing 2.00 D of hyperopic retinal defocus. Sub- and perifoveal choroidal

2018 Journal of ophthalmology Controlled trial quality: uncertain

29. Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness

: Medical University of Vienna Information provided by (Responsible Party): Gerhard Garhofer, Medical University of Vienna Study Details Study Description Go to Brief Summary: Dry eye disease (DED) is a common ocular disease, especially in the elderly population. Despite many treatment approaches, instillation of topical lubricants remains the mainstay of therapy. However, most of the topical lubricants available are not very well characterised and data about efficacy is sparse. The aim of the present (...) pilot study is to investigate the effect of topically administered lipid based eye drops on tear film lipid layer thickness in subjects with dry eye disease, Meibomian gland dysfunction, blepharospasm and healthy subjects. Tear film lipid layer and tear film thickness will be assessed using the Lipiview II interferometer and OCT. Measurements will be performed before instillation of the eye drops and every 10 minutes after instillation for one hour. One eye will receive lipid based eye drops

2018 Clinical Trials

30. Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery

Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery (iPERME) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2018 Clinical Trials

31. The Role of 2% Rebamipide Eye Drops Related to Conjunctival Differentiation in Superoxide Dismutase-1 (Sod1) Knockout Mice. Full Text available with Trip Pro

The Role of 2% Rebamipide Eye Drops Related to Conjunctival Differentiation in Superoxide Dismutase-1 (Sod1) Knockout Mice. The superoxide dismutase-1 knockout (Sod1-/-) mouse is an age-related dry eye mouse model. We evaluated the role of 2% rebamipide ophthalmic solution on the conjunctiva and ocular surface alterations in Sod1-/- mice.Rebamipide eye drops (2%) were instilled in six 50-week-old male Sod1-/- mice and six C57BL/6 strain wild-type (WT) male mice four times a day for 2 weeks (...) time (P = 0.003) and vital staining scores significantly improved in the Sod1-/- mice after treatment. Treatment with 2% rebamipide eye drops significantly decreased the corneal fluorescein (P = 0.0093) and Rose Bengal (P = 0.002) staining scores in the Sod1-/- mice. We showed a notable increase in SPDEF and a marked decrease in transglutaminase-1 and involucrin immunohistochemistry stainings, together with a significant increase in SPDEF (P = 0.0003) and a significant decline in transglutaminase-1

2018 Investigative Ophthalmology & Visual Science

32. Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

, Layout table for eligibility information Ages Eligible for Study: 50 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Diagnosis in the study eye of active, pathologic, newly diagnosed and previously untreated, subfoveal choroidal neovascular (CNV) lesions secondary to neovascular AMD Aged 50 years or older Demonstrate the ability, or have a family member who is willing and able, to instill topical ocular drops in the study (...) into the study after providing written informed consent. Participants who are eligible for the study will be centrally randomized at Day 1 to one of three doses of PAN-90806 Eye Drops. Participants will be instructed to apply one drop of PAN-90806 to the ocular surface of the identified study eye once daily for twelve (12) weeks. Participants will return for follow-up visits at Week 2, Week 4, Week 8, Week 12, 1 week after stopping PAN-90806 treatment and 1 month after stopping PAN-90806 treatment. Study

2018 Clinical Trials

33. Eye Drop Dispensers: Safety, Efficacy and Comfort.

Party): Asaf Achiron, Wolfson Medical Center Study Details Study Description Go to Brief Summary: One aspect to eye drop adherence is successful instillation of the drops; however, it is well known that many patients struggle with this task. Difficulties may include aiming their drops,extending their neck, preventing excess drop leakage, avoiding contamination of the bottle tip and generating enough force to expel a drop from the bottle. Instillation aids are devices that aim to ameliorate one (...) or more of these barriers. Several eye drop dispensers had been developed in order to improved outcomes of eye drop instillation, including improved rates of successful administration and increased patient satisfaction compared to standard eye drop bottles. In this study we aim to compare the eye drops various installation aids Condition or disease Intervention/treatment Phase Glaucoma Cataract Healthy Subjects Device: Eye Drop Dispenser TYPE Opticare Device: Eye Drop Dispenser Autodrop Not Applicable

2018 Clinical Trials

34. A Phase I Safety and Tolerability Study of PP-001 Eye Drops in Healthy Adult Volunteers

A Phase I Safety and Tolerability Study of PP-001 Eye Drops in Healthy Adult Volunteers A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03769454 Recruitment Status : Recruiting First Posted : December 7, 2018 Last Update Posted : December 17, 2018

2018 Clinical Trials

35. Micro-instillation of fluorescein with an inoculation loop for ocular surface staining in dry eye syndrome. Full Text available with Trip Pro

Micro-instillation of fluorescein with an inoculation loop for ocular surface staining in dry eye syndrome. To describe and validate the micro-instillation of fluorescein on the ocular surface by a disposable calibrated inoculation loop to improve corneal and conjunctival staining quality.Accuracy and precision of the volume of 0.5% sodium fluorescein collected by a single use 1 μl-calibrated inoculation loop were measured using a precision balance. Twenty patients (40 eyes) suffering from dry (...) eye syndrome were enrolled in a prospective interventional nonrandomized study. Fluorescein was instilled with the loop, and slit-lamp images were taken within 30 seconds using cobalt blue light with and without a yellow barrier filter. For comparison, after a washout period, the same images were retaken after instillation of one drop of fluorescein from a single-dose unit. The main outcome measure was the staining quality assessed by three experts, blind to the instillation method. Patient

2017 Acta ophthalmologica

36. Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome

the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome Actual Study Start Date : March 29, 2018 Estimated Primary Completion Date : February 2019 Estimated Study Completion Date : February 2019 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: LO2A 1 drop of sodium hyaluronate instilled into each eye 4 times daily Drug (...) : LO2A eye drops Sodium hyaluronate Active Comparator: Systane Ultra UD 1 drop of Systane Ultra UD instilled into each eye 4 times daily Drug: Systane Ultra UD Active Ingredients; Polyethylene Glycol Propylene Glycol Outcome Measures Go to Primary Outcome Measures : Change in corneal / conjunctival staining score using the National Eye Institute/Industry(NEI) Industry Grading System [ Time Frame: 3 months form the basline ] NEI/Industry Workshop Conjunctival Staining Grading System. Devitalized

2017 Clinical Trials

37. Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye Full Text available with Trip Pro

Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye PurposeTo assess the safety and efficacy of an eye drop combining osmoprotectants, carboxymethylcellulose and hyaluronic acid (O/CMC/HA) in reducing symptomatic, moderate to severe dry eye, compared with HA.MethodsIn this investigator-masked, randomised study, patients instilled 1-2 drops/eye of O/CMC/HA or HA (2-6 times/day) for 3 months. Primary (...) endpoint: mean change in Global Ocular Staining Score (GOSS) from baseline at day 35. Noninferiority of O/CMC/HA was tested in the per-protocol population; if achieved, superiority was tested in the intent-to-treat population. Secondary efficacy endpoints: mean change from baseline in GOSS, Ocular Surface Disease Index (OSDI), Schirmer score, tear break-up time (TBUT), corneal/conjunctival staining, conjunctival hyperaemia, symptoms, and patient/investigator assessments.ResultsBaseline characteristics

2017 Eye Controlled trial quality: uncertain

38. A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye

that the performance of CBL-102 Eye Drops is non-inferior to that of Vismed® Multi eye drops in subjects with moderate to severe keratoconjunctivitis sicca after 28 days, and to assess the safety of CBL-102 Eye Drops during a 90-day period with treatment administered 3 to 6 times per day. The primary performance endpoint for this study is the mean change from baseline (CFB) in the study eye at Visit 4 (Day 28 ± 3 days) in ocular surface fluorescein staining score. Condition or disease Intervention/treatment Phase (...) % sodium hyaluronate Device: Vismed Multi eye drops Vismed Multi eye drops, 3 to 6 times per day for 3 months Outcome Measures Go to Primary Outcome Measures : Total ocular surface fluorescein staining score at Visit 4 [ Time Frame: Baseline (Day 0), Visit 4 (Day 28) ] The primary performance endpoint for this study is the mean change from baseline (CFB) in the study eye in ocular surface fluorescein staining score according to a scale from 0 to 15, combining corneal, nasal and temporal bulbar

2017 Clinical Trials

39. An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

into the inferior conjunctival cul-de-sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. Change From Baseline in Wetting Distance [ Time Frame: week 8 ] The Schirmer test without anesthesia was performed to measure aqueous tear secretion prior to the instillation of any dilating or eye drops Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk (...) An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

40. Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

provided by (Responsible Party): Shire Study Details Study Description Go to Brief Summary: Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open-angle glaucoma. Condition or disease Intervention/treatment Phase Primary Open-angle Glaucoma (POAG) Ocular Hypertension Drug: SHP639 (n=60) Drug: Placebo Comparator (n=24) Phase 1 Study Design Go to Layout table for study (...) Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>